Phase 1 N=68 Randomized Double-blind Basic Science

A Study of LY3502970 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Bottom Line

View on ClinicalTrials.gov: NCT04426474 ↗

Enrolled (actual)

Serious AEs

1.5%

Results posted

May 2026

Primary outcome: Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug — 1; 0; 0; 0 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: LY3502970 (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Eli Lilly and Company
Primary completion: Jul 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	1; 0; 0; 0; 0; 0	—
SECONDARY Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970	101; 57.9; 97.9; 191; 218	—
SECONDARY PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970	1480; 850; 1600; 3120; 3520	—
SECONDARY Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)	-1.14; -2.02; -3.00; -2.85; -2.42; -2.29	—
SECONDARY PD: Change From Baseline to Week 12 in Fasting Insulin	-9.71; -12.20; -5.46; 15.16; 7.30; -1.32	—

Summary

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Eligibility Criteria

Inclusion Criteria

Have type 2 diabetes mellitus (T2DM) for at least 6 months
Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
Have had a stable body weight for the 3 months prior to screening (less than [<]5% body weight change)
Males and females (not considered woman of childbearing potential)

Exclusion Criteria

Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
Any glucose-lowering medications other than metformin within 3 months prior to screening

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04426474). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.